- MediPharm Labs (TSX:LABS) CEO David Pidduck will step down on January 23, 2026, and will remain on the Board to support the transition
- CFO Greg Hunter has been appointed Interim CEO, continuing his CFO duties while the Board evaluates long‑term leadership plans
- Pidduck and Hunter are credited with strengthening MediPharm’s operations, including restructuring efforts, improved profitability, and the integration of VIVO Cannabis Inc.
- MediPharm Labs stock (TSX:LABS) last traded at $0.07
MediPharm Labs (TSX:LABS) announced that chief executive officer, David Pidduck will step down from his role, effective January 23, 2026. The company’s Board of Directors has appointed Greg Hunter, currently chief financial officer, to serve as interim chief executive officer while it evaluates long‑term leadership options. Hunter will continue to serve simultaneously as CFO during the interim period.
Pidduck, who joined MediPharm at a challenging time for the business, is credited by the company with helping stabilize operations and reposition the organization for growth. During his tenure, MediPharm executed a series of restructuring initiatives aimed at improving efficiency and profitability. He also oversaw the integration of VIVO Cannabis Inc., which was acquired in April 2023—a transaction the company described as transformative for its product and operational footprint.
Although stepping down from day‑to‑day management, Pidduck will remain on the company’s Board of Directors to support continuity and assist with the leadership transition.
In announcing the appointment, the Board highlighted Hunter’s contributions since assuming the CFO role in February 2021. According to the company, Hunter has led cost‑reduction efforts, strengthened financial and operational controls, and played a significant role in shaping commercial strategy. His work with the sales, marketing, and product teams included pricing improvements, support for key customer initiatives, negotiation of commercial terms, and alignment of manufacturing capacity with market demand. MediPharm noted that these efforts contributed to stronger execution, improved margins, and enhanced competitiveness.
Beyond his financial background, Hunter brings more than two decades of experience from cross‑functional leadership roles at global organizations, including Johnson & Johnson (NYSE:JNJ) and Baxter (NYSE:BAX), as well as work within private equity‑backed companies. The Board stated that his commercial, operational, and general management experience positions him well to advance the company’s strategic priorities during the transition period.
“His leadership played a key role in strengthening MediPharm’s financial trajectory and guiding the company through challenging market conditions,” Chris Taves, chair of the board, commented in a media statement. “We are equally pleased to have a seasoned leader like Greg step into the Interim CEO role during this transition and the Board is confident in his ability to drive execution, operational discipline, and focused growth in the months ahead.”
MediPharm Labs has not provided a timeline for its CEO search but said the process is underway as it evaluates long‑term leadership needs.
MediPharm develops and manufactures pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products.
MediPharm Labs stock (TSX:LABS) last traded at $0.07 and has climbed 15.38 per cent since this time last year.
Join the discussion: Find out what the Bullboards are saying about MediPharm Labs and check out Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.For full disclaimer information, please click here.
